Abstracts tagged "therapy and vasculitis"

Abstract Number: 1776 • 2017 ACR/ARHP Annual Meeting
Adverse Events for Discontinuation of Immunosuppressants and Outcome of Their Re-Administration in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single Center Study in Japan
Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan
Background/Purpose: The combination of immunosuppressants and glucocorticoid is recommended for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, adverse events of immunosuppressants sometimes…
Abstract Number: 1969 • 2015 ACR/ARHP Annual Meeting
Can We Predict the Relapse of Giant Cell Arteritis?
Alojzija Hocevar, Rok Ješe, Ziga Rotar, Sonja Praprotnik, Matija Tomšič and Saša Čučnik, Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Relapses during glucocorticoid (GC) tapering are frequent in giant cell arteritis (GCA). Anemia at the time of GCA diagnosis was a predictor of flare…
Abstract Number: 1793 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of IFN-Alpha in Induction and Maintenance of Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). Single Center Observational Study
Benjamin Seeliger¹, Martin Foerster¹, Anne Moeser¹, Janett Happe¹, Claus Kroegel¹ and Thomas Neumann², ¹Jena University Hospital, Internal Medicine I, Jena, Germany, ²Jena University Hospital, Internal Medicine III, Jena, Germany
Background/Purpose: To evaluate the efficiency and safety of IFN-alpha in induction and maintenance of remission in patients with EGPA and to describe its effects on…
Abstract Number: 2783 • 2013 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine For Maintenance In Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis: Follow Up At 39 Months
Benjamin Terrier¹, Christian Pagnoux², Alexandre Karras³, Chahera Khouatra⁴, Olivier Aumaître⁵, Pascal Cohen⁶, Francois Maurier⁷, Olivier Decaux⁸, Hélène Desmurs-Clavel⁹, Pierre Gobert¹⁰, Thomas Quemeneur¹¹, Claire Blanchard-Delaunay¹², Pascal Godmer¹³, Xavier Puéchal¹⁴, Luc Mouthon¹⁵ and Loic Guillevin¹⁶, ¹Internal Medicine, Cochin University Hospital, Paris, France, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁴CHU Lyon, Lyon, France, ⁵Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁷HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁸Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁹Internal Medicine, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, ¹⁰Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹¹Internal medicine, CHR de Valenciennes, Valenciennes, France, ¹²Internal Medicine, Hôpital de Niort, Niort, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁶Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France
Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis: Follow up at 39 months.Background/Purpose: Rituximab was shown to be as effective as cyclophosphamide to…
Abstract Number: 2632 • 2013 ACR/ARHP Annual Meeting
Long Term Outcome Of Neuro-Behçet’s Disease
Nicolas Noel¹, Remy Bernard², Bertrand Wechsler³, Matthieu Resche-Rigon², Du Boutin⁴, Jean-Charles Piette⁵, Aurélie Drier⁶, Didier Dormont⁶, Patrice Cacoub⁴ and David Saadoun⁷, ¹APHP, Hopital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Le Kremlin Bicêtre, France, ²Biostatistics, Hopital Saint-Louis, Paris, France, ³Internal Medecine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ⁶Neuroradiology, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁷DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France
Background/Purpose: Neurological involvement occurs in 5.3 to up to 59% of patients with Behçet’s disease (BD). Although the clinical and imaging features of neuro-Behçet’s disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].